Biotech: Page 35
-
Getty Images
BridgeBio strikes drug royalty deal for cash infusion
The biotech will receive $500 million upon FDA approval of its rare disease drug acoramidis after selling 5% sales royalties to two investment firms.
By Ned Pagliarulo • Jan. 18, 2024 -
Getty Images
Comanche Biopharma raises $75M to fund preeclampsia drug testing
The biotech is developing an RNA-based therapy for what it describes as a root cause of the pregnancy-related complication, which affects millions of women.
By Delilah Alvarado • Jan. 17, 2024 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Getty Images
Kyverna sets plans for IPO in test of biotech enthusiasm
The offering is the fifth outlined by a biotech startup this month, suggesting companies are becoming more willing to gauge investors’ appetite for new stock offerings.
By Kristin Jensen • Jan. 17, 2024 -
NIAID. (2019). "T Regulatory Cells" [Microscope image]. Retrieved from Flickr.
Tr1x, a new biotech, joins ‘Treg’ chase with $75M fundraise
The startup is focusing on immune cells called Tr1 cells, which it claims could be important in treating autoimmune conditions like graft-versus-host disease.
By Ben Fidler • Jan. 17, 2024 -
Permission granted by ClinicalMind
Sponsored by ClinicalMindSimplifying speaker engagement in Pharma: A holistic approach
Relationships with Speaker Bureau faculty are among the most important that a biopharmaceutical company nurtures.
Jan. 16, 2024 -
Brian Tucker / BioPharma Dive/BioPharma Dive
The biopharma industry outlook on 2024: Guarded optimism for a rebound
A stock market run and a flurry of dealmaking have buoyed a sector that spent much of 2023 in a downturn. Can the momentum last?
By Ned Pagliarulo • Jan. 16, 2024 -
Getty Images
Allakos to lay off half of staff, scrap drug after study setback
The restructuring adds to a wave of industry layoffs. The Californian biotech is at least the third this year to plan a workforce reduction of 50% or more.
By Ben Fidler • Jan. 16, 2024 -
Win McNamee via Getty Images
Deep DiveWomen’s health companies, battling under-investment in research, see growing opportunity
While investment remains lower than in other areas of drug R&D, executives and VCs speak of progress for a field that’s been overlooked in the past.
By Delilah Alvarado • Jan. 16, 2024 -
David Dee Delgado via Getty Images
Backed by billionaires, a new biomedical institute tests an unorthodox approach
Arena BioWorks, which will be led by Harvard University scientist Stuart Schreiber, seeks to blend academic and venture capital drug research models.
By Ned Pagliarulo • Jan. 12, 2024 -
Permission granted by Recursion Pharmaceuticals
Q&ARecursion’s Chris Gibson on AI in biotech and ‘virtuous cycles’
The AI specialist caught the attention of many attendees to last week’s J.P. Morgan conference, where advanced computing’s impact on biotech was a much-discussed topic.
By Gwendolyn Wu • Jan. 12, 2024 -
Getty Images
Venture funding, dealmaking slowed in biotech last year: Pitchbook
Though the number of financings from private investors is down year over year, the size of those rounds has remained high, especially for drugmakers with human data in hand.
By Gwendolyn Wu • Jan. 11, 2024 -
Courtesy of Eisai
EU regulators to consult advisers in review of Eisai Alzheimer’s drug
As a result of the planned consultation, Eisai now expects an approval decision on Leqembi in Europe by the end of June, rather than March.
By Kristin Jensen • Jan. 11, 2024 -
anouchka via Getty Images
Newly optimistic, biotech investors weigh lessons of sector’s downturn
Investors and executives interviewed by BioPharma Dive at J.P. Morgan say new companies have to be leaner, hire more conservatively and focus on their first medicines quickly.
By Ben Fidler • Jan. 11, 2024 -
Danielle Ternes/BioPharma Dive
JPM24: Novartis’ head start, FTC fallout and Bluebird’s price defense
Radiopharma drugmakers spoke with BioPharma Dive about chasing Novartis in the hot field, while Bluebird’s CEO explained the company’s sickle cell therapy pricing.
By Ben Fidler , Ned Pagliarulo , Gwendolyn Wu • Jan. 10, 2024 -
Danielle Ternes/BioPharma Dive
JPM24: Pfizer’s tough sell, the next Karuna and building a biotech platform
Albert Bourla acknowledged Pfizer’s difficult 2023, while PureTech’s Daphne Zohar spoke with BioPharma Dive about building neuroscience startups.
By Ben Fidler , Delilah Alvarado • Jan. 9, 2024 -
Danielle Ternes/BioPharma Dive
JPM24: Nvidia’s AI dreams, Sarepta’s rosy outlook and Jeff Jonas’ new job
The chip maker struck a new deal with Amgen last Monday, while Sarepta brought news of strong sales to the J.P. Morgan Healthcare Conference.
By Gwendolyn Wu , Delilah Alvarado , Ben Fidler • Jan. 8, 2024 -
Getty Images
Year of biotech layoffs leaves industry looking for spark
Small and mid-sized drugmakers shed at least 10,000 jobs in 2023, according to data compiled by BioPharma Dive. However, recent deal and stock market momentum have brought some optimism.
By Delilah Alvarado , Ned Pagliarulo • Jan. 8, 2024 -
Getty Images
5 questions facing emerging biotech in 2024
An unusual FTC challenge could have implications for startups, while industry watchers gauge whether the sector’s recent momentum will end a lengthy funding crunch.
By Gwendolyn Wu • Jan. 8, 2024 -
Permission granted by Ionis Pharmaceuticals and Metagenomi
Gene editing startup Metagenomi files for an IPO
The Emeryville, California-based gene therapy developer has several preclinical programs in development with Moderna, Ionis and Affini-T.
By Gwendolyn Wu • Jan. 6, 2024 -
Getty Images
An unusual drugmaker raises north of $100M for ecstasy-based PTSD therapy
Lykos Therapeutics, formerly known as MAPS Public Benefit Corp., recently submitted its MDMA capsules for FDA approval, following two positive studies.
By Jacob Bell • Jan. 5, 2024 -
Courtesy of Intellia Therapeutics
Intellia to lay off staff, cut some early research
The CRISPR specialist joins some of its genetic medicine peers in trimming staff, announcing an “organizational streamlining” to focus resources on prioritiy drug programs.
By Gwendolyn Wu • Jan. 4, 2024 -
Getty Images
Allogene to shift strategy in bid to reposition CAR-T
The company plans to restructure and will start a new late-stage study testing whether its “off-the-shelf” therapy can boost cure rates when used early on.
By Ben Fidler • Jan. 4, 2024 -
Getty Images
Novo taps Flagship startups to develop drugs for obesity, MASH
The research deals with Omega Therapeutics and Cellarity are the first under a broad alliance Novo struck with Flagship last spring.
By Kristin Jensen • Jan. 4, 2024 -
Permission granted by Erin Beach/Moonwalk Biosciences
A new startup from Feng Zhang and an ex-Illumina executive zeroes in on the epigenome
Moonwalk Biosciences, the latest biotech co-founded by Zhang, joins other startups aiming to alter gene expression without changing DNA.
By Gwendolyn Wu • Jan. 4, 2024 -
Michael M. Santiago via Getty Images
Goldman Sachs gets into biotech investing with new venture fund
The $650 million fund exceeded Goldman’s target and comes amid cautious optimism that biotech could rebound from a lengthy downturn.
By Kristin Jensen • Jan. 3, 2024
Previous
